Intranasal desmopressin (DDAVP, DDVP, Minirin, Stimate Nasal Spray) is no longer indicated for primary nocturnal enuresis and is associated with an increased risk of severe hyponatremia (possibly ...
Three forms of nasal spray are being recalled because they could contain too much of a man-made hormone used in treating conditions including a type of diabetes and frequent urination. Ferring ...
Ferring Pharmaceuticals US is voluntarily recalling all lots on the market of DDAVP® Nasal Spray 10 mcg/0.1mL, Desmopressin Acetate Nasal Spray 10 mcg/0.1mL, and STIMATE® Nasal Spray 1.5 mg/mL listed ...
The batch was distributed between August 14, 2018 and September 5, 2018. One nonfatal adverse event has been reported during the timeframe the affected product was distributed. Ferring has announced a ...
Feb. 18, 2005 — The U.S. Food and Drug Administration (FDA) has approved a first-time generic formulation of terconazole vaginal cream 0.4% for the treatment of vulvovaginal candidiasis; a first-time ...
ROCKVILLE, Md., Dec.4, 2007-- FDA notified healthcare professionals and patients of the Agency's request that manufacturers update the prescribing information for desmopressin to include important new ...
On August 5, 2020, Ferring Pharmaceuticals announced a recall of three nasal sprays due to superpotency of the ingredients. The recalled products are DDAVP Nasal Spray, Desmopressin Acetate Nasal ...
WASHINGTON The Food and Drug Administration has notified health care professionals and patients of its request that manufacturers update the prescribing information for desmopressin. Desmopressin ...
PARSIPPANY, N.J., Oct. 22, 2014 /PRNewswire-USNewswire/ – Ferring Pharmaceuticals is pleased to announce that the company has acquired DDAVP® (desmopressin acetate) from Sanofi. Ferring is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results